[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Tanaka H, Masuda H, Komai Y, Yokoyama M, Iwai A, Numao N, Sakai Y, Saito K, Fujii Y, Kobayashi T, Kawakami S, Kihara K: [Primary adenocarcinoma of the female urethra treated by multimodal therapy]. Hinyokika Kiyo; 2009 Jan;55(1):43-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the female urethra treated by multimodal therapy].
  • Magnetic resonance imaging showed a tumor surrounding the urethra, which invaded to the vesical triangle and the anterior vaginal wall.
  • Pathological examinations of the transurethral and transvaginal needle biopsy specimen suggested mucinous adenocarcinoma.
  • First, the patient received local chemoradiotherapy and systemic chemotherapy using a fluoropyrimidine drug TS-1 and cisplatin.
  • The tumor markers declined to within normal limits after this preoperative therapy.
  • Histopathological examination of the surgical specimen showed mutinous adenocarcinoma invading to the vesical triangle and the anterior vaginal wall.
  • The final diagnosis was urethral adenocarcinoma, pT4N0, Stage IV.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Urethral Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227213.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Libby B, Chao D, Schneider BF: Non-surgical treatment of primary female urethral cancer. Rare Tumors; 2010;2(3):e55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-surgical treatment of primary female urethral cancer.
  • Primary carcinomas of the female urethra are extremely rare, with an annual incidence of less than ten in one million.
  • However, there have been several case reports demonstrating the efficacy of chemoradiation in the treatment of female urethral cancer.
  • In this report we present two cases of female primary urethral adenocarcinoma that were treated by concomitant chemotherapy and external beam radiotherapy, followed by interstitial brachytherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139970.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994528
  • [Keywords] NOTNLM ; high-dose rate / low-dose rate. / urethral cancer
  •  go-up   go-down


3. Awakura Y, Nonomura M, Itoh N, Maeno A, Fukuyama T: Adenocarcinoma of the female urethral diverticulum treated by multimodality therapy. Int J Urol; 2003 May;10(5):281-3
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the female urethral diverticulum treated by multimodality therapy.
  • The diagnosis by urethroscopy and radiological evaluation was localized urethral diverticular tumor.
  • Pathological examination of the biopsy specimen revealed adenocarcinoma.
  • The patient received two courses of intra-arterial and systemic chemotherapy using cisplatin, 5-fluorouracil and leucovorin, followed by radiation to the urethra.
  • The tumor shrunk markedly after chemotherapy.
  • Adenocarcinoma of the female urethral diverticulum is rare and has been treated by surgery and/or radiation.
  • The present case is the first case of it being treated by multimodality therapy including chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diverticulum / therapy. Urethral Neoplasms / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694472.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Ahmad NA, Memon A, Hussainy A: Abdominoperineal excision of male lower urinary tract for synchronous adenocarcinoma of urethra and urinary bladder. Urology; 2005 Mar;65(3):591
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominoperineal excision of male lower urinary tract for synchronous adenocarcinoma of urethra and urinary bladder.
  • Urethral adenocarcinoma is the least common histologic subtype of a rare primary carcinoma of the male urethra.
  • This report is of a 40-year-old morbidly obese man with synchronous adenocarcinoma of the bulbar urethra and bladder, treated surgically by en bloc abdominoperineal penoprostatocystectomy.
  • The pleural recurrence, after a disease-free period of 2 years, responded well to platinum-docetaxel-based systemic chemotherapy.
  • Synchronous occurrence of adenocarcinoma of the urethra and bladder has not been previously reported.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasms, Multiple Primary / surgery. Urethral Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780385.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


5. Ouzaid I, Hermieu JF, Dominique S, Fernandez P, Choudat L, Ravery V: Management of adenocarcinoma of the female urethra: case report and brief review. Can J Urol; 2010 Oct;17(5):5404-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adenocarcinoma of the female urethra: case report and brief review.
  • INTRODUCTION: We present a case of a differentiated adenocarcinoma of the female urethra, which caused dysuria and voiding dysfunction.
  • RESULTS: An ultrasound-guided biopsy showed a urethral carcinoma.
  • CONCLUSION: Urethral carcinoma is a rare malignancy.
  • A biopsy is necessary to make a diagnosis.
  • Advanced disease should be treated with a multimodality of options including neoadjuvant radiotherapy given concomitantly with chemotherapy followed by surgery.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Urethral Neoplasms / radiotherapy. Urethral Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Middle Aged. Pelvic Exenteration. Treatment Outcome. Urologic Surgical Procedures / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20974039.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  •  go-up   go-down


6. Tamas EF, Nielsen ME, Schoenberg MP, Epstein JI: Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Mod Pathol; 2007 Aug;20(8):828-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied 28 cases of lymphoepithelioma-like carcinoma of the bladder, one case in the renal pelvis, and one in the urethra.
  • Seventeen cases (56.7%) were pure with the remaining mixed with other patterns of carcinoma, including invasive urothelial carcinoma (n=10), invasive adenocarcinoma (n=3), and squamous cell carcinoma (n=2).
  • The surface demonstrated carcinoma in situ (CIS) in six cases, noninvasive high-grade papillary urothelial carcinoma in three cases, and in situ adenocarcinoma in one case.
  • Treatment consisted of radical cystectomy in 13/30 cases (43%); partial cystectomy in 4/30 cases (13%); nephrectomy in one case (3%), and transurethral resection often followed by radiation or chemotherapy in 12/30 (40%) cases.
  • Of the three pure cases treated by chemotherapy, two were free of disease at 4 and 65 months and the third had recurrent disease at 17 months.
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Disease-Free Survival. Epithelial Cells / pathology. Female. Follow-Up Studies. Humans. Lymphocytes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541442.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Ohyama C, Takyu S, Yoshikawa K, Suzuki H, Tezuka F, Hasuda A, Inaba Y, Hoshi S, Orikasa S: Adenocarcinoma arising from the prostatic duct mimicking transitional cell carcinoma. Int J Urol; 2001 Jul;8(7):408-11
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma arising from the prostatic duct mimicking transitional cell carcinoma.
  • A 71-year-old man was first diagnosed with primary transitional cell carcinoma of the prostate with a skip lesion on the distal urethra.
  • The patient received three courses of intra-arterial chemotherapy of cisplatin (CDDP) and pirarubicin (THP-ADM) followed by a radical prostatectomy.
  • Histopathologic examination of the prostatectomy specimen revealed adenocarcinoma invasion along the prostatic duct extending to the peripheral acini, which was diagnosed as ductal adenocarcinoma.
  • This rare histopathologic feature should be recognized as 'ductal carcinoma of the prostate', to distinguish it from papillary adenocarcinoma or adenocarcinoma with endometrioid features.
  • CDDP-based chemotherapy followed by radical prostatectomy may be one of the promising therapeutic modalities for this rare entity.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Transitional Cell / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11442666.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


8. Moslemi MK, Sadighi Gilani MA, Moslemi AA, Arabshahi A: Fournier gangrene presenting in a patient with undiagnosed rectal adenocarcinoma: a case report. Cases J; 2009;2:9136

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fournier gangrene presenting in a patient with undiagnosed rectal adenocarcinoma: a case report.
  • Infection most commonly arises from the skin, urethra, or rectal regions.
  • Despite appropriate therapy, mortality in this disease is still high.
  • In the course of medical and surgical treatment the presence of extensive rectal adenocarcinoma was discovered.
  • Skin grafting of necrotic areas was performed and systemic rectal cancer chemotherapy initiated after full stabilization.
  • Early diagnosis and treatment decrease the morbidity and mortality of this life threatening condition.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2009 May;181(5):2120-6 [19286224.001]
  • [Cites] Prog Urol. 2009 Feb;19(2):75-84 [19168009.001]
  • [Cites] Med Sci Monit. 2009 Feb;15(2):CS34-39 [19179975.001]
  • [Cites] Actas Urol Esp. 2008 Nov-Dec;32(10):1024-30 [19143295.001]
  • [Cites] Mikrobiyol Bul. 2008 Oct;42(4):707-11 [19149096.001]
  • [Cites] J Pediatr Surg. 2008 Dec;43(12):e39-42 [19040919.001]
  • [Cites] Arch Esp Urol. 1999 Sep;52(7):721-7 [10540762.001]
  • [Cites] Surg Today. 2007;37(7):558-63 [17593474.001]
  • [Cites] Eur J Surg Oncol. 1997 Aug;23(4):367-8 [9315070.001]
  • [Cites] J Urol. 1992 Mar;147(3):711-2 [1538468.001]
  • [Cites] J Urol. 1978 Mar;119(3):369-71 [642092.001]
  • [Cites] Surg Clin North Am. 2002 Dec;82(6):1213-24 [12516849.001]
  • [Cites] J Urol. 2008 Sep;180(3):944-8 [18635215.001]
  • (PMID = 20062653.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803933
  •  go-up   go-down


9. Hamasaki T, Kondo Y, Ogata Y, Yoshida K, Kimura G, Shimizu H, Nishimura T: Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder. Int J Clin Oncol; 2010 Feb;15(1):109-11
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder.
  • Pathological examination diagnosed poorly differentiated urothelial carcinoma of the urethra with broad prostatic permeation.
  • Computed tomography (CT) showed lymph node metastases from para-aortic to right/left external iliac and left obturator nodes, so clinical stage T3N2M0 carcinoma of the prostatic urethra was diagnosed.
  • Given the presence of lymph node metastases, neoadjuvant chemotherapy using cisplatin 70 mg/m(2), ifosfamide 1.2 g/m(2) and docetaxel 70 mg/m(2) (PIT) was considered.
  • After chemotherapy, CT showed complete response (CR) of all lymph nodes.
  • Pathological findings of surgical specimens showed no residual carcinoma in the prostatic urethra or lymph nodes, although prostatic adenocarcinoma was recognized.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Prostatic Neoplasms / secondary. Urethral Neoplasms / drug therapy
  • [MeSH-minor] Aged. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoadjuvant Therapy. Prostatectomy. Prostatic Hyperplasia / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1996 Nov;48(5):703-10 [8911513.001]
  • [Cites] Am J Clin Pathol. 1963 Aug;40:183-9 [14060023.001]
  • [Cites] J Urol. 1973 Mar;109(3):457-60 [4348139.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Hinyokika Kiyo. 2000 Jul;46(7):495-8 [10965459.001]
  • [Cites] Urology. 1984 Dec;24(6):544-9 [6506393.001]
  • [Cites] J Urol. 1997 Aug;158(2):338-41 [9224298.001]
  • [Cites] Br J Urol. 1979 Dec;51(6):575-8 [534844.001]
  • [Cites] J Urol. 2005 Nov;174(5):1771-5; discussion 1775-6 [16217281.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1671-8 [10738226.001]
  • [Cites] Urology. 2007 Jan;69(1 Suppl):50-61 [17280908.001]
  • [Cites] Hinyokika Kiyo. 1970 Apr;16(4):157-61 [5463380.001]
  • (PMID = 20087614.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Bakkali H, Benjaafar N, Mansouri A, Errihani H, Kettani F, Benchekroun A, El Gueddari Bel K: [Primary adenocarcinoma of the male urethra. A case report]. Cancer Radiother; 2002 Dec;6(6):358-62
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the male urethra. A case report].
  • Primary adenocarcinoma of the male urethra is very uncommon, accounts for 5% of primary urethral cancers.
  • All types of urethral carcinomas account for less than 1% of urinary malignancies in man.
  • The prognosis remains poor despite the wide surgical treatment.
  • The place of chemotherapy combined with radiotherapy must be defined by other studies.
  • We report a case of primary locally advanced adenocarcinoma arising in the bulbo-membranous urethra.
  • He was treated by combined external beam radiotherapy (total dose 67Gy) and chemotherapy (Cisplatinum).
  • A marked reduction of tumor volume has been noted but the patient died because of the appearance of bone metastasis which failed to the systemic therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Neoplasm Metastasis. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12504773.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Doddamani D, Ansari MS, Gupta NP, Aron M, Singh I, Datta Gupta S: Mesonephroid adenocarcinoma of the bladder and urethra: a case report. Int Urogynecol J Pelvic Floor Dysfunct; 2002;13(1):47-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesonephroid adenocarcinoma of the bladder and urethra: a case report.
  • Mesonephric or mesonephroid adenocarcinoma of the bladder may be a malignant form of nephrogenic adenoma or nephroid metaplasia.
  • We report another case of mesonephroid adenocarcinoma of the bladder and urethra which was treated with transurethral resection and subsequent chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Mesoderm / pathology. Nephrons / pathology. Urethral Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Female. Humans. Methotrexate / therapeutic use

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11999207.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Benchekroun A, Nouini Y, Zannoud M, Kasmaoui el H, Jira H, el Alj HA: [Ureteral adenocarcinoma in men: a case report]. Ann Urol (Paris); 2003 Jun;37(3):131-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ureteral adenocarcinoma in men: a case report].
  • Adenocarcinoma of urethra is a rare tumour, which occurs more often in female than in male.
  • The localizations on bulbomenbranous urethra, most frequent, have worse prognostic than those of penile urethra.
  • Because of scarcity of these tumours there is not therapeutic consensus.
  • The treatment is based on the tripod surgery, more or less mutilating, chemotherapy and radiotherapy associated or managed in a separate way.
  • We report the case of a young patient with adenocarcinoma of the posterior urethra treated by a protocol of radio-chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urethral Neoplasms / pathology
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Male

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12872605.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park SH, Park JO, Kim WS, Kang WK, Lee HM, Choi HY, Lim H: Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract. Med Oncol; 2009;26(2):186-92
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract.
  • Clinical information regarding the clinical behavior and chemotherapy outcome of non-transitional cell carcinomas of the urothelial tract are incomplete due to their rarity.
  • The object of this study was to evaluate the clinical features and the efficacy of palliative chemotherapy in advanced non-transitional cell carcinomas of the urothelial tract.
  • We analyzed the clinical records of 21 consecutive patients who received palliative chemotherapy for unresectable or metastatic non-transitional cell carcinomas of the urothelial tract between January 1995 and November 2007.
  • All the 21 patients received first-line chemotherapy with platinum-based regimens which are known to be effective in transitional cell urothelial carcinomas.
  • The primary sites of involvement were the bladder, urethra, urachus, and ureter in 43%, 29%, 19%, and 10% of the patients, respectively.
  • Adenocarcinoma was the most common histological type (67%); squamous cell carcinoma and small cell carcinoma comprised 24 and 10% of the histologic types, respectively.
  • With a median duration of follow-up of 32 months (range, 12-71 months), the median overall survival for all 21 patients from the day of first-line chemotherapy was 13 months (95% CI, 6.8-19.2).
  • Univariate analysis showed a better median overall survival in patients with adenocarcinoma, compared to non-adenocarcinomas (47 vs. 10 months, P = 0.049).
  • The median overall survival of patients who received platinum-based palliative chemotherapy for advanced non-transitional cell carcinomas was comparable to previous studies for patients with transitional cell carcinomas.
  • Adenocarcinomas appear to have a favorable prognosis for the survival of the patients who received platinum-based chemotherapy for advanced non-transitional cell carcinomas.
  • [MeSH-major] Carcinoma / drug therapy. Palliative Care. Urologic Neoplasms / drug therapy. Urothelium
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2007 Feb;69(2):255-9 [17320659.001]
  • [Cites] Eur Urol. 2003 Dec;44(6):672-81 [14644119.001]
  • [Cites] Oncology. 2005;69(5):391-8 [16319510.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1639-45 [15073851.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 5:v118-22 [16807438.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1066-73 [1607913.001]
  • [Cites] Eur Urol. 2000 Jan;37(1):85-9 [10671791.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):297-303 [16342065.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5B):3865-9 [17094415.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1921-7 [10784633.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):1050-5 [2189954.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1172-8 [15700264.001]
  • [Cites] BJU Int. 2005 Mar;95(4):497-502 [15705067.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2876-81 [10561365.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):220-8 [14665607.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4602-8 [16034041.001]
  • [Cites] BJU Int. 2004 Jan;93(2):216-20 [14690486.001]
  • (PMID = 18988001.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Tiguert R, Ravery V, Madjar S, Gousse AE: [Acute urinary retention secondary to clear cell adenocarcinoma of the urethra]. Prog Urol; 2001 Feb;11(1):70-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute urinary retention secondary to clear cell adenocarcinoma of the urethra].
  • The authors report a case of primary clear cell cancer of the urethra in a woman presenting with acute urinary retention.
  • The diagnosis was based on cystoscopy and confirmed by histological examination of urethral biopsies.
  • Treatment consisted of urethrocystectomy with creation of an "Indiana pouch".
  • She was treated with 3 courses of chemotherapy (mitomycin and 5-fluorouracil) combined with radiotherapy.
  • This case report emphasizes the rarity of this histological type and describes the management of urinary retention in a woman when an underlying specific disease is suspected.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Urethral Neoplasms / complications. Urinary Retention / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11296650.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


15. Noorani S, Rao AR, Callaghan PS: Urethral metastasis: an uncommon presentation of a colonic adenocarcinoma. Int Urol Nephrol; 2007;39(3):837-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urethral metastasis: an uncommon presentation of a colonic adenocarcinoma.
  • INTRODUCTION: Metastases to the urethra are a rare clinical entity.
  • In this report, however we describe a case of urethral metastases from a colonic cancer origin where the urethral lesion was the presenting symptom.
  • CASE REPORT: A 69-year-old woman presented with a swelling at the urethral opening.
  • Per vaginal examination revealed a hard tender lesion situated at the external urethral meatus with contact bleeding.
  • Excision biopsy revealed adenocarcinoma.
  • Subsequent investigations revealed that the patient did indeed have a sigmoid adenocarcinoma and underwent chemotherapy with a view to anterior resection and pelvic exenteration.
  • DISCUSSION: Metastases to the urethra are rare.
  • Treatment options have to be individualised to the extent of the disease and the symptoms of the patient.
  • Atypical presentations of urethral lesions should be viewed with suspicion.
  • A biopsy of the lesion is the only way of confirming diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Sigmoid Neoplasms / pathology. Urethral Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Apr;163(4):1245-6 [10737510.001]
  • [Cites] Arch Pathol Lab Med. 2002 Sep;126(9):1057-63 [12204054.001]
  • [Cites] ANZ J Surg. 2004 Oct;74(10):925-7 [15456455.001]
  • [Cites] Arch Surg. 1973 Dec;107(6):906-8 [4751838.001]
  • [Cites] Int Braz J Urol. 2003 Sep-Oct;29(5):431-3 [15745589.001]
  • [Cites] Indian J Cancer. 1994 Mar;31(1):31-3 [8063334.001]
  • (PMID = 17318345.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


16. Kurosaka S, Irie A, Mizoguchi H, Okuno N, Iwabuchi K, Baba S: Advanced clear-cell adenocarcinoma of the bladder successfully treated by radical surgery with adjuvant chemoradiotherapy. Int J Clin Oncol; 2005 Oct;10(5):362-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced clear-cell adenocarcinoma of the bladder successfully treated by radical surgery with adjuvant chemoradiotherapy.
  • The tumor seemed to have arisen from the bladder or urethra, and bilateral iliac lymphadenopathy was seen.
  • Her urethral mucosa looked intact according to the results of cystourethroscopy.
  • Histopathological examination of the biopsy specimens showed clear-cell adenocarcinoma.
  • Macroscopically, the tumor had arisen from the trigone of the bladder, and histopathological examination of the tumor revealed adenocarcinoma exhibiting solid clear cells with glandular and papillary patterns.
  • Postoperatively, three courses of systemic combination chemotherapy with 5-fluouracil (FU) and cisplatin, along with a total of 45 Gy of irradiation during the second course of chemotherapy, were conducted.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Cystectomy. Female. Humans. Lymph Node Excision. Middle Aged. Pelvis. Urethra / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2002 Aug;9(8):467-9 [12225345.001]
  • [Cites] Urol Int. 2003;71(2):228-30 [12890970.001]
  • [Cites] Eur J Gynaecol Oncol. 1996;17(1):13-6 [8750509.001]
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):39-48 [11121861.001]
  • [Cites] Mod Pathol. 1993 Mar;6(2):225-8 [8483895.001]
  • [Cites] J Urol. 1968 Oct;100(4):466-9 [5677385.001]
  • [Cites] Histopathology. 1990 Jun;16(6):601-4 [2376401.001]
  • [Cites] Urology. 1984 Mar;23(3):303-4 [6199882.001]
  • [Cites] J Urol. 1990 Jan;143(1):122-5 [2294240.001]
  • (PMID = 16247666.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Pan CC, Chiang H, Chang YH, Epstein JI: Tubulocystic clear cell adenocarcinoma arising within the prostate. Am J Surg Pathol; 2000 Oct;24(10):1433-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulocystic clear cell adenocarcinoma arising within the prostate.
  • Neoplasms resembling ovarian common epithelial-type tumors, including clear cell adenocarcinomas, rarely occur in the lower urinary tract of men.
  • When they do, they develop in the urethra or urinary bladder.
  • The clinical as well as the pathologic features are consistent with a clear cell adenocarcinoma as seen in the female genital tract rather than a typical prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Fluorouracil / administration & dosage. Humans. Immunohistochemistry. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Proteins / analysis. Testicular Neoplasms / drug therapy. Testicular Neoplasms / secondary. Testicular Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11023108.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Nagano M, Hasui Y, Ide H, Itoi T, Takehara T, Osada Y: Primary adenocarcinoma arising from a paraurethral cyst in a female patient. Urol Int; 2002;69(3):244-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma arising from a paraurethral cyst in a female patient.
  • A very rare case of primary adenocarcinoma arising from a paraurethral cyst in a 63-year-old woman is reported.
  • Initially she was diagnosed as having a simple paraurethral cyst because of absent communication with the urethra.
  • The resected paraurethral cyst was histologically associated with adenocarcinoma.
  • We also performed chemotherapy composed of methotrexate, vinblastine, Adriamycin and cisplatin because of lymph node metastasis.
  • Our treatment, however, was not effective and the patient died of systemic metastases.
  • [MeSH-major] Adenocarcinoma / pathology. Cysts / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Combined Modality Therapy / methods. Fatal Outcome. Female. Humans. Middle Aged. Ultrasonography, Doppler. Urethral Diseases / pathology. Urogenital Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12372897.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Segura Huerta A, Molina Saera J, Palomar Abad L, Pellín Ariño L, Guerrero Zotano A, Calderero Aragón V: [Advanced urethral carcinoma. Which is the best management of a infrequent disease?]. Actas Urol Esp; 2004 Jan;28(1):57-61
Genetic Alliance. consumer health - Best Vitelliform Macular Dystrophy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced urethral carcinoma. Which is the best management of a infrequent disease?].
  • Urethral cancer is an uncommon tumor (<0.1% of all genitourinary neoplasms).
  • Most of them are squamous carcinoma, adenocarcinomas are about 5% of all urethral cancer.
  • Surgery is the only curative treatment.
  • Chemotherapy (CT) and radiotherapy (RT) must be used in patients in which surgery is not possible.
  • Due to the low incidence of this neoplasm is not well established the best therapeutic approach.
  • We present the case of a female (35 years old) with a diagnosis of urethral adenocarcinoma.
  • Surgery was impossible and the patient received chemotherapy and radiotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Urethral Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15046483.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


20. Wakahara T, Yamamoto S, Fujita S, Akasu T, Onouchi S, Moriya Y: A case of advanced rectal adenocarcinoid tumor with long-term survival. Jpn J Clin Oncol; 2010 Jul;40(7):690-3
Genetic Alliance. consumer health - Adenocarcinoid Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 58-year-old man underwent total pelvic exenteration with extended lateral lymph node dissection for rectal adenocarcinoid tumor invading the urethra with lateral lymph node metastasis.
  • Postoperatively, the patient received combination chemotherapy of fluorouracil and leucovorin as an adjuvant therapy.
  • Three years and 5 years after the initial surgery, the patient developed left groin and left external iliac lymph node recurrences, and lymphadenectomy was performed each time.
  • There is no consensus on the indication of surgical treatment for adenocarcinoid tumor.
  • However, in advanced cases, an aggressive surgical procedure might result in long-term survival when resectable.
  • [MeSH-major] Adenocarcinoma / diagnosis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Survivors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20338947.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Preti M, Micheletti L, Ghiringhello B, Privitera S, Condello V, Chieppa P, Massobrio M: [Vulvar Paget's disease. Clinico-pathologic review of the literature]. Minerva Ginecol; 2000 May;52(5):203-11
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with VPD are at risk for a second synchronous or metachronous neoplasia: colo-rectal adenocarcinoma (more frequent in perianal localization of VPD), cervical adenocarcinoma, carcinoma of the transitional epithelium from the renal pelvis to urethra and mammary carcinoma.
  • Therapy for intraepithelial VPD is wide and deep surgical resection comprising all the skin appendages.
  • When association with underlying invasive adenocarcinoma or stromal invasion is histologically confirmed, vulvar surgical approach must be integrated with inguino-femoral lymphadenectomy.
  • The role of chemotherapy and radiotherapy in the multimodal approach to extensive or recurring VPD is still controversial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11048477.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] ITALY
  • [Number-of-references] 69
  •  go-up   go-down


22. Gadducci A, Cionini L, Romanini A, Fanucchi A, Genazzani AR: Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol; 2006 Dec;60(3):227-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Modifications of the surgical technique of deep femoral lymphadenectomy and the mapping of sentinel node can offer new interesting therapeutic perspectives.
  • Locally advanced squamous cell carcinoma of the vulva has been long surgically treated with en-block radical vulvectomy and bilateral inguinal-femoral lymphadenectomy plus partial resection of urethra, vagina or anum, or by exenteration, with severe postsurgical complications, poor quality of life, and unsatisfactory survival rates.
  • 5-Fluorouracil [5-FU] or 5-FU- and cisplatin-based chemotherapy concurrent with irradiation followed by tailored surgery represents an attractive therapeutic option for advanced disease, planned to avoid such ultra-radical surgical procedures and, hopefully, to improve patient outcome.
  • Chemotherapy has also been used in neoadjuvant setting, with contrasting and generally unsatisfactory results, and in palliative treatment of patients with distant metastases.
  • Surgery is the primary treatment also for vulvar malignancies other than squamous cell carcinoma, whereas the clinical usefulness of adjuvant irradiation or chemotherapy is still to be defined.
  • Primary chemoradiation can be also used for advanced carcinoma of the Bartholin gland or for advanced adenocarcinoma associated with extramammary Paget's disease.
  • The drugs used for chemotherapy of metastatic melanomas or sarcomas of the vulva are the same employed for the melanomas or sarcomas developed in other sites.
  • [MeSH-major] Vulvar Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Neoplasm Metastasis. Recurrence

  • Genetic Alliance. consumer health - Vulvar cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945551.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 167
  •  go-up   go-down


23. Anderson CR, McNiel EA, Gillette EL, Powers BE, LaRue SM: Late complications of pelvic irradiation in 16 dogs. Vet Radiol Ultrasound; 2002 Mar-Apr;43(2):187-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When external beam radiation therapy is administered to the pelvis, normal tissues irradiated may include the colon, small intestine, urethra, bladder, bone, and spinal cord.
  • Medical records of all dogs treated with curative intent external beam radiation therapy to the pelvic region between 1993 and 1999 were reviewed.
  • Patients with follow-up longer than 9 months or any patient that developed late complications earlier than 9 months were evaluated.
  • Diseases treated included transitional cell carcinoma of the bladder, transitional cell carcinoma of the prostate, and anal sac apocrine gland adenocarcinoma.
  • Four dose/fractionation schemes were used: 49.5 Gy in 3.3 Gy fractions, 54 Gy in 3.0 Gy fractions, 54 Gy in 2.7 Gy fractions, and 18 Gy intraoperative radiation therapy followed by 43 Gy external beam radiation therapy in 2.9 Gy fractions.
  • Implantable chemotherapy in the form of an OPLA-Pt sponge was used in six dogs as a radiation potentiator.
  • All dogs with severe late effects received 3 or 3.3 Gy per fraction, and 80% received radiation potentiators.
  • In the seven dogs that received 2.7 Gy or 2.9 Gy per fraction, late effects were classified as none (n = 5), mild colitis (n = 1), and moderate colitis (n = 1).
  • Radiation therapy can be administered to the pelvic region with a minimal risk of late effects to the colon by giving smaller doses per fraction and avoiding systemic radiation potentiators.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11954816.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement